Fennec Pharmaceuticals Inc. (FENC) Income Statement

Revenue has built consistent sequential momentum for six consecutive quarters, rising from $7.0M to $17.9M without a single down quarter. The accelerating growth rate—85.2% in 2026Q2 versus 72.6% in 2026Q1—suggests commercial adoption is still expanding, but investors should monitor whether this pace reflects durable demand or favorable channel stocking dynamics.

The company's gross margin profile is structurally superior to most small-cap biotechs, yet SG&A has grown nearly 90% over eight quarters versus gross profit growth of approximately 135%. This suggests the commercial infrastructure build-out is not yet generating proportional operating leverage, and the sustainability of SG&A discipline remains a key variable for margin trajectory.

The near-parity between gross profit and SG&A in the latest quarter indicates the company is still operating below its breakeven efficiency threshold, with incremental revenue flowing primarily into commercial spend rather than operating income. If SG&A growth decelerates toward the high single digits while revenue continues accelerating, operating leverage could inflect meaningfully—but this remains speculative absent evidence of cost discipline.

The last two quarters—2026Q1 and 2026Q2—represent the first back-to-back profitable periods in the dataset, suggesting the company may be transitioning from a loss-making commercial build-out to sustainable operations. However, the inflection remains fragile: a single quarter of SG&A escalation, as seen in 2025Q4 ($14.5M), was sufficient to push operating income deeply negative, underscoring how sensitive profitability remains to expense timing.